Andrew Armstrong is an Oncology physician. ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4101 N Roxboro St
Durham, NC 277042121
Telephone
919-684-8111Registry record last updated 7 Mar 2023.
Clinical trials
- COMPASS Study for Metastatic Castration-resistant Prostate Cancer
Sponsor: Duke University
- A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Sponsor: Andrew J. Armstrong, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma Europe LtdProgram year202513 payments$33,984openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20255 payments$26,190openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202520 payments$19,995openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
67.1%Cytochrome P450 17A1 Inhibitor24.1%Abiraterone Acetate100%Part D≥23 patientsAnti-androgens19.7%Nubeqa100%Part D≥20 patients+ 4 more classes in this area
Metabolism & gastrointestinal
27.2%Corticosteroid27.2%Prednisone100%Part D≥39 patientsSensory organs
3.3%Corticosteroid3.3%Dexamethasone100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC
Duke University
FY2025$647,291R01CA256157
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”